FDA accepts Iveric Bio's NDA, grants priority review for GA drug

On the heels of a second Phase III win in geographic atrophy last year, Iveric Bio is now waiting at the FDA’s doors for its final decision, which is set to come after competitor Apellis Pharmaceuticals hears from the regulator later this month.